Boeing, Snowflake, Five Below Rise Premarket; Apple Falls

By Peter Nurse
Investing.com -- Stocks in focus in premarket trade on Thursday, December 2nd. Please refresh for updates.
-
Apple (NASDAQ: AAPL ) stock fell 2.8% after Bloomberg reported that demand for the tech giant’s latest batch of iPhones is weakening due to price and availability issues.
-
Boeing (NYSE: BA ) stock rose 5% after China's aviation authority issued an airworthiness directive on the 737 MAX plane, potentially allowing the return of this key model to service in China after more than two and a half years.
-
Snowflake (NYSE: SNOW ) stock soared 14% after the data platform provider reported strong fourth-quarter guidance, reporting upbeat third-quarter results bolstered by its international expansion.
-
- Crowdstrike (NASDAQ: CRWD ) stock rose 0.3% after the cybersecurity company announced strong quarterly earnings as well as a substantial increase in new subscription customers.
-
Okta (NASDAQ: OKTA ) stock rose 2% after the cloud identity management company reported strong third-quarter results, posting revenue growth of 61% from last year and beating its own guidance.
- Five Below (NASDAQ: FIVE ) stock rose 9.4% after the discount store posted better than expected results on both the top and bottom-line in its third quarter.
- Dollar General (NYSE: DG ) stock fell 3.1% after the discount chain narrowed its full-year sales forecast on Thursday, as returning consumer appetite for discretionary items helped counter easing demand for groceries.
- Square (NYSE: SQ ) stock fell 0.5% after the payments company announced it was changing its name to ‘Block’ as it looks to expand into new technologies like blockchain.
-
Simon Property Group (NYSE: SPG ) stock rose 1.4% after Morgan Stanley (NYSE: MS ) reiterated an ‘outperform’ rating on the real estate group, saying its recent dip creates an attractive entry point, with more than 20% upside.
- Vir Biotechnology (NASDAQ: VIR ) stock soared 13% and GlaxoSmithKline (NYSE: GSK ) ADRs rose 0.6% after analysis of the antibody-based Covid-19 therapy the partners are developing has indicated the drug is effective against the new omicron variant.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or